- Home
- LRMR vs LEO Comparison
LRMR vs LEO Comparison
Compare LRMR & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- LEO
- Stock Information
- Founded
- LRMR N/A
- LEO 1987
- Country
- LRMR United States
- LEO United States
- Employees
- LRMR N/A
- LEO N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- LEO Trusts Except Educational Religious and Charitable
- Sector
- LRMR Health Care
- LEO Finance
- Exchange
- LRMR Nasdaq
- LEO Nasdaq
- Market Cap
- LRMR 426.9M
- LEO 391.2M
- IPO Year
- LRMR N/A
- LEO N/A
- Fundamental
- Price
- LRMR $3.19
- LEO $6.28
- Analyst Decision
- LRMR Strong Buy
- LEO
- Analyst Count
- LRMR 9
- LEO 0
- Target Price
- LRMR $19.44
- LEO N/A
- AVG Volume (30 Days)
- LRMR 639.4K
- LEO 200.2K
- Earning Date
- LRMR 03-13-2025
- LEO 01-01-0001
- Dividend Yield
- LRMR N/A
- LEO 4.01%
- EPS Growth
- LRMR N/A
- LEO N/A
- EPS
- LRMR N/A
- LEO 0.04
- Revenue
- LRMR N/A
- LEO N/A
- Revenue This Year
- LRMR N/A
- LEO N/A
- Revenue Next Year
- LRMR N/A
- LEO N/A
- P/E Ratio
- LRMR N/A
- LEO $152.00
- Revenue Growth
- LRMR N/A
- LEO N/A
- 52 Week Low
- LRMR $3.01
- LEO $4.98
- 52 Week High
- LRMR $12.91
- LEO $6.50
- Technical
- Relative Strength Index (RSI)
- LRMR 37.56
- LEO 60.14
- Support Level
- LRMR $3.06
- LEO $6.11
- Resistance Level
- LRMR $3.52
- LEO $6.33
- Average True Range (ATR)
- LRMR 0.22
- LEO 0.05
- MACD
- LRMR 0.02
- LEO 0.01
- Stochastic Oscillator
- LRMR 15.66
- LEO 78.26
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.